JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266513

Human ETFA knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ETFA KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

View Alternative Names

Alpha-ETF, EMA, ETFA_HUMAN, Electron transfer flavoprotein alpha polypeptide, Electron transfer flavoprotein alpha subunit, Electron transfer flavoprotein subunit alpha mitochondrial, Electron transferring flavoprotein alpha polypeptide, GA2, Glutaric aciduria II

3 Images
Western blot - Human ETFA knockout HEK-293T cell line (AB266513)
  • WB

Lab

Western blot - Human ETFA knockout HEK-293T cell line (AB266513)

Lanes 1-2 : Merged signal (red and green). Green - ab110316 observed at 35 kDa. Red - loading control ab52901 observed at kDa.

ab110316 Anti-ETFA antibody [2B11AE8] was shown to specifically react with ETFA in wild-type HEK-293T cells. Loss of signal was observed when knockout cell line ab266513 (knockout cell lysate ab257943) was used. Wild-type and ETFA knockout samples were subjected to SDS-PAGE. ab110316 and Anti-beta Tubulin [EP1331Y] - Microtubule Marker (ab52901) were incubated overnight at 4° at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (ab216777) and Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-ETFA antibody [2B11AE8] (<a href='/en-us/products/primary-antibodies/etfa-antibody-2b11ae8-ab110316'>ab110316</a>) at 1/1000 dilution

Lane 1:

Wild-type HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 40 µg

Lane 2:

ETFA knockout HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 40 µg

Lane 2:

Western blot - Human ETFA knockout HEK-293T cell line (ab266513)

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-680rd-preadsorbed-ab216777'>ab216777</a>) at 1/10000 dilution

Predicted band size: 35 kDa,81 kDa

Observed band size: 35 kDa

false

Cell Culture - Human ETFA knockout HEK-293T cell line (AB266513)
  • Cell Culture

Lab

Cell Culture - Human ETFA knockout HEK-293T cell line (AB266513)

Representative images ETFA knockout HEK293T cells, low and high confluency examples (top left and right respectively) and wild-type HEK293T cells, low and high confluency (bottom left and right respectively) showing typical adherent, epithelial-like morphology. Images were captured at 10X magnification using a EVOS M5000 microscope.

Sanger Sequencing - Human ETFA knockout HEK-293T cell line (AB266513)
  • Sanger seq

Unknown

Sanger Sequencing - Human ETFA knockout HEK-293T cell line (AB266513)

Homozygous : Insertion of the selection cassette in exon 1

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266513-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266513 Human ETFA knockout HEK-293T cell line", "number":"AB266513-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266513-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266513-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266513 Human ETFA knockout HEK-293T cell line", "number":"AB266513-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266513-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266513-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266513 Human ETFA knockout HEK-293T cell line", "number":"AB266513-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266513-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266513 Human ETFA knockout HEK-293T cell line", "number":"AB266513-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ETFA
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ETFA or Electron-Transfer-Flavoprotein alpha subunit is an essential part of the mitochondrial respiratory chain. This protein which has a molecular mass of approximately 34 kDa functions in the transfer of electrons from acyl-CoA dehydrogenases to the main respiratory chain for energy production. ETFA is commonly expressed in tissues with high-energy demands such as the liver heart and skeletal muscle. The protein forms a heterodimeric complex with its counterpart ETFB providing a critical function in electron transfer during fatty acid oxidation.
Biological function summary

ETFA operates as an important part of the electron transfer process within the mitochondria. It acts as one-half of the heterodimeric electron-transfer flavoprotein complex teaming with ETFB. This complex facilitates electron transfer from a range of acyl-CoA dehydrogenases to ETF dehydrogenase which then continues the process of electron transfer to coenzyme Q in the respiratory chain. This action is key to the breakdown of fats enabling energy extraction and processing.

Pathways

ETFA has important roles in fatty acid beta-oxidation and amino acid catabolism. It engages in these pathways by transferring electrons as mentioned interfacing with other proteins like ETF dehydrogenase. This positioning within the mitochondrial matrix enables ETFA to assist in converting fat and protein substrates into energy which the cell can use. Its molecular interactions highlight its integral position in maintaining energy homeostasis.

Problems with ETFA lead to glutaric acidemia type 2 a metabolic disorder that impairs the body's ability to oxidize fatty acids and some amino acids. Deficiencies in ETFA function disrupt the electron transport to the respiratory chain causing an accumulation of intermediary metabolites. These disruptions can relate to or involve other mitochondrial components and proteins like ETFB or ETFDH. Correct diagnosis and understanding of ETFA's role in such conditions are instrumental for targeted therapeutic approaches.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com